Ground Swell Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Ground Swell Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$45K	Buy	402 +138	+52%	+$13.1K	0.09%	245
2014 Q2	$25K	Buy	+264	New	+$18.5K	0.05%	330

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ground Swell Capital's VRTX Position: Q3 2014 in Review

Ground Swell Capital increased its Vertex Pharmaceuticals (VRTX) stake by 52% in Q3 2014, buying an estimated $13.1K and bringing the position to 402 shares worth $45K. The position accounts for 0.09% of the portfolio, ranked #245.

Ground Swell Capital first reported a position in VRTX in Q2 2014 and has held it in 2 quarters since. 431 funds tracked by Wall St. Rank hold VRTX as of Q3 2014.

Ground Swell Capital held 402 shares of Vertex Pharmaceuticals worth $45K as of Q3 2014.
Ground Swell Capital bought 138 Vertex Pharmaceuticals shares in Q3 2014, an estimated $13.1K.
Vertex Pharmaceuticals made up 0.09% of Ground Swell Capital's portfolio in Q3 2014, its #245 holding.
Ground Swell Capital first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
431 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.